Mibavademab (also known as REGN-4461) is an investigational, fully human monoclonal antibody that targets leptin receptor (LEPR), a key receptor involved in the regulation of energy homeostasis and metabolism. By binding to LEPR, mibavademab functions as a leptin receptor agonist, mimicking the action of the hormone leptin. This activation is intended to restore leptin signaling in individuals with congenital leptin receptor deficiency or other forms of leptin receptor dysfunction, thereby reducing hyperphagia (extreme hunger), improving metabolic parameters, and promoting weight loss. It is being developed as a potential therapy for severe, early-onset obesity due to LEPR deficiency and related metabolic disorders.